How many people have taken acne treatment Accutane? Millions -- many millions.

First made available in 1982, acne drug Accutane was sold by pharmaceutical giant Roche Pharmaceuticals for 27 years, or until Roche issued an Accutane recall in 2009. However, generic Accutane remains available from other manufacturers, which began producing such generic Accutane as Amnesteem, Sotret and Claravis in 2002, after Roche’s patent expired.

Not long before that, in the year 2000, Roche had amassed 13 million Accutane users throughout the world. Of those 13 million, a total of at least 5 million lived in the United States.

Since then, many more people in the U.S. and across the globe have continued to use Accutane. These millions of people, sadly, are subject to a variety of Accutane side effects, including IBD, or inflammatory bowel disease.

While Roche was selling acne drug Accutane to its millions of potential victims, it was making billions of dollars in profits.

Roche reaped as much as $3 billion in profits in a single year from selling defective acne medication Accutane. Even as its Accutane sales wound down as Roche prepared to withdraw Accutane form the market in 2009, it was earning as much as $1.7 billion from Accutane.

Those earnings came at the expense of many thousands of Accutane side effects victims, including many who suffer from a lifelong and incurable IBD such as Crohn’s disease or ulcerative colitis. Treatment even can require colon removal surgery.

Such victims deserve justice for their injuries, and they can seek legal remedies through an Accutane lawsuit.

In this way, Accutane victims can pursue fair and fitting financial compensation for their medical expenses, their lost wages and their pain and suffering, all of which occurred as a result of Roche’s negligence in selling its defective drug.

To begin, simply submit the free case evaluation form on the website of Accutane-Lawsuit-Lawyer.com, or call toll-free to 1-800-339-0606. Then the process of gaining economic recovery -- and justice -- can begin.